

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

CHP-212

RRID:CVCL_1125

Type: Cell Line

Proper Citation

RRID:CVCL_1125

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1125

Proper Citation: RRID:CVCL_1125

Description: Cell line CHP-212 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:6113887](#), [PMID:7139592](#), [PMID:12068308](#), [PMID:15720811](#), [PMID:15892104](#), [PMID:18724359](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28350380](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#), [PMID:39255063](#)

Comments: Characteristics: Intermediate type (I-type) (PubMed=15720811)., Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CHP-212

Synonyms: CHP 212, CHP212, NB9, NB-9, Children's Hospital of Philadelphia-212

Cross References: CLO:CLO_0002467, CLO:CLO_0002473, CLO:CLO_0050261, EFO:EFO_0002133, CLDB:cl771, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2273, BioGRID_ORCS_Cell_line:595, BioSample:SAMN03472322, BioSample:SAMN03473208, BioSample:SAMN10988326, cancercellines:CVCL_1125,

Cell_Model_Passport:SIDM00910, ChEMBL-Cells:CHEMBL3308101, ChEMBL-Targets:CHEMBL1075423, Cosmic:724826, Cosmic:906820, Cosmic:920244, Cosmic:1161987, Cosmic:2131574, Cosmic-CLP:906820, DepMap:ACH-000120, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906820, GEO:GSM563361, GEO:GSM886930, GEO:GSM887996, GEO:GSM1366405, GEO:GSM1669678, GEO:GSM2371223, GEO:GSM2394381, IARC_TP53:21227, IGRhCellID:CHP212, LiGeA:CCLE_207, LINCX_LDP:LCL-1964, PharmacDB:CHP212_200_2019, PRIDE:PXD030304, Progenetix:CVCL_1125, PubChem_Cell_line:CVCL_1125, RCB:RCB0477, Wikidata:Q54813267

ID: CVCL_1125

Record Creation Time: 20220427T215505+0000

Record Last Update: 20260829T231838+0000

Ratings and Alerts

No rating or validation information has been found for CHP-212.

No alerts have been found for CHP-212.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yokomura M, et al. (2026) Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity. Cancer immunology, immunotherapy : CII, 75(1), 33.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Fries LE, et al. (2025) Variability in proliferative and migratory defects in Hirschsprung disease-associated RET pathogenic variants. American journal of human genetics, 112(4), 863.

Stöber MC, et al. (2024) Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity. Cell reports, 43(9), 114711.

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. Cell reports. Medicine, 5(3), 101468.

Nakao-Ise Y, et al. (2023) Induction of MYCN-amplified neuroblastoma differentiation through NMYC suppression using PPAR- γ antagonist. *Journal of clinical biochemistry and nutrition*, 73(3), 191.

Szwarc MM, et al. (2023) FAM193A is a positive regulator of p53 activity. *Cell reports*, 42(3), 112230.

Loh AHP, et al. (2022) Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse. *Frontiers in oncology*, 12, 939460.

Malone CF, et al. (2021) Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. *Cancer discovery*, 11(9), 2282.

Huang H, et al. (2021) Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. *Cell reports*, 36(2), 109363.

Jachimowicz RD, et al. (2019) UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. *Cell*, 176(3), 505.